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hronic obstructive pulmonary 
disease (COPD) is a global 
epidemic of major proportions 
that is predicted to become the third 
most common cause of death and 
ﬁ  fth most frequent cause of chronic 
disability by 2020. In developed 
countries it is mainly caused by 
cigarette smoking, but the reasons 
why only a proportion (10%–20%) of 
smokers develop progressive airﬂ  ow 
limitation is currently unknown. The 
disease is characterized by a chronic 
inﬂ  ammatory process predominantly 
in the small airways and lung 
parenchyma, with increased numbers 
of macrophages, neutrophils, and 
T lymphocytes [1]. The difference 
between smokers without COPD and 
smokers with COPD appears to be 
the intensity rather than the nature 
of the inﬂ  ammatory process. This 
inﬂ  ammation in the small airways is 
associated with ﬁ  brosis and increases 
with the severity of airﬂ  ow limitation 
[2], which has led to the view that 
COPD represents an ampliﬁ  cation of 
the normal inﬂ  ammatory response 
to inhaled irritants such as cigarette 
smoke. 
T Lymphocytes in COPD
T lymphocytes were ﬁ  rst reported to 
be increased in patients with COPD by 
Finkelstein and colleagues, who showed 
a correlation between the number 
of T lymphocytes/mm3 of lung and 
the extent of emphysema [3]. It was 
later shown that both CD4+ (T helper) 
and CD8+ (suppressor/cytotoxic) T 
cells were increased in the airways 
and lung parenchyma of patients with 
COPD, with a predominance of CD8+ 
cells [4,5]. This is in contrast to the 
ﬁ  ndings in asthma, in which there is a 
predominance of CD4+ cells, which are 
predominantly of the T helper 2 (Th2) 
pattern, with increased expression of 
interleukin (IL)-4, IL-5, 
and IL-13 (see Glossary), 
and which are associated 
with an increased number 
of eosinophils. In smokers 
who develop COPD there 
appears to be activation 
of adaptive immunity, 
with the inﬁ  ltration of 
CD8+ and CD4+ cells in 
the alveolar walls and 
small airways and—in 
patients with the most 
severe disease—the 
presence of lymphoid 
follicles that contain a 
core of B lymphocytes 
surrounded by T cells 
[2]. This activation 
presumably follows on 
from the initial and then 
sustained innate immune response 
characterized by increased numbers of 
macrophages and neutrophils; it may 
involve the migration of dendritic cells 
from the epithelium to the local lymph 
nodes and presentation of antigenic 
substances to T cells, resulting in clonal 
expansion of CD4+ and, to an even 
greater extent, CD8+ cells.
The study by Grumelli et al. (2004) 
published in this issue of PLoS 
Medicine takes the story forward [6]. 
The CD4+ and CD8+ cells appear to 
be fully activated, as they would be 
after being presented with antigens, 
and they show predominantly a T 
helper 1 (Th1)/cytotoxic T 1 (Tc1) 
pattern, with increased expression 
of interferon-γ (IFN-γ) and Th1 
chemokines. This is consistent with 
the recent demonstration of increased 
expression of IL-12 in bronchial 
biopsies of patients with COPD and 
activation of the transcription factor 
STAT-4 in T cells, subsequent STAT-4 
nuclear translocation, and IFN-γ gene 
induction, and thus a Th1 commitment 
in the T cells [7]. 
As well as producing the cytokines 
IL-2 and IFN-γ, Th1 and Tc1 cells 
also express the chemokine receptor 
CXCR3 and the ligands that activate 
this receptor, IFN-γ inducible protein 
10 (IP-10, CXCL10), monokine 
induced by IFN-γ (CXCL9), and IFN-
inducible T cell α chemoattractant 
(CXCL11). There is an increase in the 
expression of IP-10 in the airways of 
patients with COPD and an increase 
in the number of CXCR3+ cells [8]. 
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Figure 1. In Emphysema, a Self-Perpetuating Loop May Lead to 
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CXCR3 is expressed on Th1/Tc1 
cells, macrophages, and epithelial 
cells. Release of CXCR3-activating 
chemokines would attract Th1 and 
Tc1 cells into the lungs, and these cells 
then release IFN-γ, which releases more 
CXCR3 chemoattractants. This results 
in a self-perpetuating loop that may 
lead to accumulation of activated Th1 
and Tc1 cells in the peripheral lung 
(Figure 1).
Role of Cytotoxic T Cells
It is likely that Th1 cells are the major 
source of IFN-γ in the lungs of patients 
with COPD and therefore drive and 
maintain the T cell response and 
promote an “immune inﬂ  ammation” 
with neutrophils and macrophages. 
However, it is the role of Tc1 cells 
that is of particular interest, as these 
cells are cytotoxic to epithelial cells 
through the release of granzymes and 
perforins, which induce apoptosis. 
Increased concentrations of perforins 
have recently been reported in the 
sputum of patients with COPD [9]. In 
support of this idea there is an increase 
in the apoptosis of alveolar cells in the 
lungs of patients with COPD, and this 
is correlated with the number of CD8+ 
cells and the severity of emphysema 
[10]. 
T Cell Perpetuation
The T cell inﬂ  ammatory response 
appears in mild COPD but increases 
markedly with disease severity. It 
is possible that the initial immune 
response becomes self-perpetuating 
because of endogenous autoantigens 
resulting from inﬂ  ammatory and 
oxidative lung injury. There are 
also antigens in tobacco, but the 
inﬂ  ammatory response appears to 
become independent of smoking status, 
and there is intense inﬂ  ammation 
even in patients who stopped smoking 
many years previously [2], as seen in 
the present study by Grumelli et al. [6]. 
Another possibility is that this chronic 
immune response is driven, or at least 
maintained, by chronic infection of the 
respiratory tract often seen in patients 
with severe disease, in which there is 
increased colonization of the lower 
airways. These infections could act as 
co-stimulators, or by antigenic mimicry 
or as polyclonal activators they could 
provide a persisting antigenic stimulus 
and maintain the inﬂ  ammatory 
process. Further studies on T cell 
receptor usage and expression of 
surface markers may give further clues 
as to the driving mechanisms for the 
increased Th1 and Tc1 cells in COPD.
Proteases
COPD is characterized by destruction 
of the lung parenchyma and loss of 
elastin due to elastolytic enzymes, 
such as neutrophil elastase and certain 
matrix metalloproteinases (MMPs). 
The predominant MMP in COPD 
appears to be MMP9, which is released 
in much larger amounts from alveolar 
macrophages of patients with COPD 
than from those of smokers without the 
disease [11]. The study by Grumelli et 
al. showed that CXCR3 ligands led to 
the expression of the elastolytic enzyme 
MMP12 in alveolar macrophages and 
that this process was increased in the 
lungs of patients with COPD. This 
ﬁ  nding provides a neat link between 
T cells and alveolar destruction, but is 
discrepant with other data that have 
failed to show signiﬁ  cant MMP12 
release from macrophages of patients 
with COPD [11].
Therapeutic Implications
There are currently no treatments that 
reduce the relentless progression of 
COPD, and none that have signiﬁ  cant 
anti-inﬂ  ammatory effects. However the 
recognition that an adaptive immune 
T cell response, most likely driven 
by antigens, may play an important 
pathophysiological role in the 
pathogenesis of COPD has important 
therapeutic implications. It is possible 
that T cell inhibitory strategies, such as 
the use of immunosuppressants, might 
be effective, although side effects may 
be a problem, and there is particular 
concern about increasing the risk of 
bacterial infection. Another approach 
might be to block the trafﬁ  cking of Th1 
and Tc1 cells to the lungs by blocking 
CXCR3, and there is now a search 
for small-molecule inhibitors of these 
receptors. Inhibition of IFN-γ signaling 
might be another approach.
The mounting evidence implicating 
T cells, and thus an adaptive immune 
response, as an important component 
of the inﬂ  ammation in COPD is 
overwhelming. A better understanding 
of the immune mechanisms involved 
in COPD is important, since it might 
lead us to new and more effective 
therapeutic approaches to this 
important disease.  
Glossary
CD4+ (helper) T cell: T lymphocyte that 
enhances the inﬂ  ammatory response
CD8+ (cytotoxic/suppressor) T cell: 
T lymphocyte that suppresses the 
inﬂ  ammatory response
CXCR3: Chemokine receptor that is 
selectively activated by IP-10, monokine 
induced by IFN-γ, and IFN-inducible T cell 
chemoattractant
Cytotoxic (Tc1) cell: T cell that is 
characterized by secretion of INF-γ
Granzyme: Enzyme released by cytotoxic 
T cells
Interferon-γ inducible protein 10 (IP-
10, CXCL10): Chemokine of 10 kDa that 
selectively activates CXCR3
Interferon-inducible T cell γ 
chemoattractant (I-TAC, CXCL11): 
Chemokine that selectively activates 
CXCR3
Interferon-γ (IFN-γ): Protein secreted by 
Th1 and Tc1 cells
Interleukin-4 (IL-4): Protein secreted by 
Th2 cells that is important in increasing 
IgE secretion
Interleukin-5 (IL-5): Protein secreted 
by Th2 cells that is important for 
eosinophilia
Interleukin-12 (IL-12): Protein secreted 
by antigen-presenting cells that 
promotes differentiation of Th1 cells
Interleukin-13 (IL-13): Protein secreted 
by Th2 cells that is important for IgE 
secretion
Matrix metalloproteinase (MMP): 
Proteolytic enzyme that degrades 
connective tissue 
MMP9, MMP12: MMPs that destroy 
elastin ﬁ  bers
Monokine induced by interferon-
γ (MIG, CXCL9): Chemokine that 
selectively activates CXCR3
Neutrophil elastase: Enzyme released 
from neutrophils that destroys elastin 
ﬁ  bers
Perforin: Protein released by cytotoxic T 
cells that induces apoptosis
STAT-4: Transcription factor speciﬁ  cally 
activated by IL-1
T helper 1 (Th1) cell: T lymphocyte that 
is characterized by secretion of INF-γ
T helper (Th2) cell: T lymphocyte that 
is characterized by increased secretion 
of the cytokines IL-4, IL-5, and IL-13; 
characteristically increased in allergic 
inﬂ  ammation
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